Skip to main content

Dianthus Therapeutics, Inc.

DNTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001690585

In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Dianthus Therapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of DNTH: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders4630−16
SharesConverted for a 1-for-16 split1.81M10.1M+8.26M (+455.1%)
Value$22.0M$136.3M+$114.3M (+519.3%)

New holders (9)

Institutions that held Dianthus Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to DNTH in Q3 2023
InstitutionSharesValue% of portfolio
FMR LLC2,218,212$29.0M0.00%
Fairmount Funds Management LLC1,928,503$26.4M3.17%
5AM Venture Management, LLC1,472,264$20.1M5.79%
Avidity Partners Management LP1,217,554$16.6M0.67%
VR Adviser, LLC927,706$12.7M1.33%
ArrowMark Colorado Holdings LLC20,788$284.2K0.00%
Jefferies Financial Group Inc.13,200$180.4K0.00%
Citigroup Inc3,868$52.9K0.00%
Qube Research & Technologies Ltd3$410.00%

Sold out (25)

Institutions that held Dianthus Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.